Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Gemcitabine+Platinium Salt+Bevacizumab Combination for Metastatic Collecting Duct Carcinoma (GETUG-AFU 24) (BEVABEL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02363751
Recruitment Status : Recruiting
First Posted : February 16, 2015
Last Update Posted : November 6, 2017
Sponsor:
Information provided by (Responsible Party):
UNICANCER

Brief Summary:
Open-label, non-randomized, multicenter, phase II, single arm non comparative trial evaluating toxicity and efficacy of gemcitabine plus platinium salt in combination with bevacizumab in first-line setting in metastatic collecting duct carcinoma.

Condition or disease Intervention/treatment Phase
Collecting Duct Carcinoma (Kidney) Drug: Bevacizumab Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 41 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Prospective Phase II Study of Gemcitabine Plus Platinium Salt in Combination With Bevacizumab (Avastin®) for Metastatic Collecting Duct Carcinoma
Study Start Date : December 2014
Estimated Primary Completion Date : July 2019
Estimated Study Completion Date : June 2021


Arm Intervention/treatment
Experimental: 1
Patients will be treated for a maximum of 6 (21 days) chemotherapy cycles (Gemcitabine+platinium salt+bevcizumab)
Drug: Bevacizumab

Patients will be treated for a maximum of 6 (21days) chemotherapy cycles (Gemcitabine+platinium salt+bevacizumab).

In case of disease control (complete, partial or stable disease) treatment with bevacizumab 15mg/Kg monotherapy every 21 days will be continued until disease progression or until the end of the 24 months of follow-up.

Other Name: Avastin




Primary Outcome Measures :
  1. Composite endpoint : Objective response rate / Progression-free survival [ Time Frame: 6 months ]

    The primary endpoint is composed of:

    • the objective response rate (CR or PR) according to RECIST criteria (V1.1) on the basis of measurable lesions defined at baseline,
    • the progression-free survival (PFS) rate at 6 months , PFS is defined as the absence of disease progression or death


Secondary Outcome Measures :
  1. Progression-free survival (PFS) [ Time Frame: 2 years max ]
    Progression-free survival (PFS) will be calculated from the date of the first dose of treatment to the date of progression or death (whichever comes first), or last date with no progression

  2. The Overall Survival (OS) [ Time Frame: 2 years max ]
    The Overall Survival (OS) will be calculated from the date of the first dose of treatment to the date of death (whatever the cause) or the date of last follow-up

  3. The toxicity will be evaluated according to the NCI-CTC scale version 4.0 [ Time Frame: 2 years max ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients should be aged ≥ 18years at the inclusion,
  2. Patients with histologically confirmed metastatic collecting duct carcinoma (medullary accepted),
  3. Available tumor samples for centralized reading by anatomopathologist,
  4. Patients with or without nephrectomy,
  5. At least one measurable lesion as per RECIST criteria (RECIST v1.1),
  6. No prior chemotherapy nor anti-angiogenic drugs ; Prior adjuvant chemotherapy of localised disease admitted if it is stopped for more than 12 months at the inclusion date.,
  7. No irradiation within 4 weeks before inclusion,
  8. Absolute neutrophil counts (ANC) ≥ 1.5 x 109/L,
  9. Platelets ≥ 100 x 109/L,
  10. Hemoglobin ≥ 9 g/dL,
  11. Hepatic function : AST and ALT ≤ 1.5 x ULN (≤ 4 x ULN in case of liver metastases); total bilirubin ≤ 1.5 x ULN; alkaline phosphatase < 2 x ULN (≤ 4 x ULN in case of bone metastases),
  12. Renal function : creatinine clearance ≥ 60 mL/min (MDRD calculation method) using cis-platin and > 30mL/min when using carboplatin,
  13. Absence of proteinuria at baseline defined by < 0.3 g of protein on urine sample or < 0.5 g/24h00 on urine collection,
  14. Prothrombin time (TP) or partial thromboplastin time (PTT) strictly less than 50% deviation from normal limits, of international normalized ratio (INR) strictly below 2, Note: The use of full-dose oral or parenteral anticoagulants as well as aspirin or clopidogrel is permitted as long as the INR or a PTT is within therapeutic limits (according to the medical standard of the institution) and the patient has been on a stable dose of anticoagulants for at least two weeks at the time of study enrolment. Prophylactic use of anticoagulants is allowed.
  15. ECG with normal or clinically insignificant as per investigator's judgement sinus rhythm,
  16. ECOG Performance Status: 0 - 2,
  17. Estimated life expectancy ≥ 12 weeks,
  18. Patients who have received the information sheet, dated and signed the informed consent form,
  19. Patient of child-bearing potential (for female patient: study entry after a menstrual period and a negative pregnancy test) must agree to use two medically acceptable methods of contraception (one for the patient and one for the partner) during the study and for 6 months after the last study treatment intake.
  20. Patients must be willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures,
  21. Patients affiliated to the Social Security System,

Exclusion Criteria:

  1. Treatment with any other investigational agent, or participation in another clinical trial within 28 days prior to enrolment,
  2. Prior systemic treatment with chemotherapy or anti-angiogenic tyrosine kinase inhibitors such as axitinib, sunitinib, sorafenib, pazopanib, tivozanib, mTOR inhibitor (Temsirolimus or everolimus) and targeted VEGF drugs such as bevacizumab and VEGF trap,
  3. Evidence of current spinal cord compression or leptomeningeal disease. Please note that patients with asymptomatic brain metastases are eligible,
  4. Another histological type of renal cancer
  5. Other malignancy within 3 years prior to inclusion (except basal cell carcinoma of the skin and/or in situ carcinoma of the cervix, and/or pT1/a bladder cancer),
  6. Uncontrolled hypertension (≥ 160 mm Hg systolic and/or ≥ 90 mm Hg diastolic) while receiving medication,
  7. Cardio-vascular disorders: congestive heart failure ≥ NYHA II, myocardial infarction or coronary artery bypass graft in the previous six months, ongoing severe or unstable angina,
  8. LVEF value strictly less than 50%,
  9. Current or recent (within 2 weeks of study enrolment) initiation of aspirin, clopidogrel), oral or parenteral anticoagulants or thrombolytic agents for therapeutic purposes,
  10. History of clinically significant hemorrhagic or thromboembolic events in the past six months, or known inherited predisposition to bleeding or thrombosis or History of abdominal fistula, GI perforation, intra-abdominal abscess or active GI bleeding within 6 months prior to the first study treatment; History of haemoptysis ≥ grade 2 (defined as ≥ 2.5 mL bright red blood per episode) within 1 month of study enrolment,
  11. Patients who underwent, according to the investigator, a significant surgery such as but not limited to , abdominal, thoracic or neurologic surgery within 28 days before the first treatment administration or patient with a wound that is not already healed at the first treatment administration or patients who underwent a minor surgical procedure including placement of a vascular access device, within 2 days of the first study treatment,
  12. Patients with active gastro-duodenal ulcer,
  13. Patients with untreated bone fracture,
  14. Peripheral neuropathy grade ≥ 2 (Toxicity Criteria-(CTCAE) v4.0),
  15. Patients with active infection requiring intravenous antibiotics at the time of first study treatment,
  16. In the opinion of the investigator, any evidence of other severe or uncontrolled systemic disease (e.g. unstable or uncompensated respiratory, cardiac, hepatic or renal disease), or any other acute or chronic medical condition that would make the patient inappropriate with this study,
  17. Immunocompromised patients, including known seropositivity for human immunodeficiency virus (HIV),
  18. Known hypersensitivity to any component of the investigational drugs or excipients,
  19. Pregnant or lactating women,
  20. Person deprived of their liberty or under judicial protection (including guardianship),
  21. Patients with significantly altered mental status prohibiting the understanding of the study or with psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule or any condition which, in the opinion of the investigator, would preclude participation in this trial. Those conditions should be discussed with the patient before registration in the trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02363751


Contacts
Layout table for location contacts
Contact: Sandra PELISSIER +33 1 44 23 55 68 s-pelissier@unicancer.fr

Locations
Layout table for location information
France
Institut de Cancérologie de l'Ouest-Site Paul Papin Recruiting
Angers, France, 49333
Contact: Rémy DELVA    (0)241 352 700 ext +33    remy.delva@ico.unicancer.fr   
CHU Besançon Recruiting
Besançon, France, 25030
Contact: Thierry N'GUYEN, Dr    +33 3 81 66 93 20    doctnguyen@hotmail.com   
Hôpital Saint André Recruiting
Bordeaux, France, 33075
Contact: Marine GROSS-GOUPIL    +33 5 56 79 58 96    marine.gross-goupil@chu-bordeaux.fr   
Centre François Baclesse Recruiting
Caen, France, 14076
Contact: Florence JOLY    (0)231 455 002 ext +33    f.joly@baclesse.fr   
Hôpital Henri Mondor Recruiting
Créteil, France, 94000
Contact: Charlotte JOLY, Dr    +33 1 49 81 25 67    charlotte.joly@hmn.aphp.fr   
Centre Oscar Lambret Recruiting
Lille, France, 59020
Contact: Fredrik LAESTADIUS, MD    (0) 320 295 971 ext +33    f-laestadius@o-lambret.fr   
Centre Léon Bérard Recruiting
Lyon, France, 69008
Contact: Aude FLECHON, Dr    +33 4 78 78 26 43    aude.flechon@lyon.unicancer.fr   
Institut Paoli-Calmettes Recruiting
Marseille, France, 13273
Contact: Gwenaelle GRAVIS, Dr    +33 4 91 22 36 28    gravisg@ipc.unicancer.fr   
ICM Val d'Aurelle Recruiting
Montpellier, France, 34298
Contact: Diego TOSI, Dr    +33 4 67 61 23 04    diego.tosi@icm.unicancer.fr   
Centre Antoine Lacassagne Recruiting
Nice, France, 06189
Contact: Jean-Marc FERRERO       jean-marc.ferrero@nice.unicancer.fr   
Hôpital Saint-Louis Recruiting
Paris, France, 75010
Contact: Stéphane CULINE    (0)142 494 247 ext +33    stephane.culine@sls.aphp.fr   
Hôpital Européen Georges Pompidou Recruiting
Paris, France, 75908
Contact: Stéphane OUDARD    (0)156 092 569 ext +33    stephane.oudard@egp.aphp.fr   
Centre Eugène Marquis Recruiting
Rennes, France, 35042
Contact: Brigitte LAGUERRE, Dr    +33 2 99 25 32 34    b.laguerre@rennes.unicancer.fr   
Centre Eugene Marquis Recruiting
Rennes, France, 35064
Contact: Brigitte LAGUERRE    (0) 299 253 234 ext +33    b.laguerre@rennes.unicancer.fr   
Institut de cancérologie de l'Ouest - Site René Gauducheau Recruiting
Saint Herblain, France, 44800
Contact: Frédéric ROLLAND, Dr    +33 2 40 67 99 76    Frederic.Rolland@ico.unicancer.fr   
CHU Strasbourg - Hôpital Civil Recruiting
Strasbourg, France, 67091
Contact: Philippe BARTHELEMY, Dr       philippe.barthelemy@chru-strasbourg.fr   
Institut Claudius Regaud Recruiting
Toulouse, France, 31059
Contact: Christine CHEVREAU    (0)531 155 050 ext +33    chevreau.christine@iuct-oncopole.fr   
CHR Bretonneau Recruiting
Tours, France, 37044
Contact: Claude LINASSIER, Dr    +33 2 47 47 99 19    claude.linassier@univ-tours.fr   
Gustave Roussy, Cancer Campus, Grand Paris Recruiting
Villejuif, France, 94805
Contact: Laurence ALBIGES    (0)142 115 410 ext +33    laurence.albiges@gustaveroussy.fr   
Sponsors and Collaborators
UNICANCER
Investigators
Layout table for investigator information
Principal Investigator: Constance THIBAULT, Dr Hôpital Européen Georges-Pompidou
Study Chair: Marc-Olivier TIMSIT, Dr Hôpital Européen Georges-Pompidou

Layout table for additonal information
Responsible Party: UNICANCER
ClinicalTrials.gov Identifier: NCT02363751     History of Changes
Other Study ID Numbers: UC-0160/1210
First Posted: February 16, 2015    Key Record Dates
Last Update Posted: November 6, 2017
Last Verified: October 2017
Keywords provided by UNICANCER:
Bellini
Metastatic
Chemotherapy
Bevacizumab
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Carcinoma, Ductal
Carcinoma, Renal Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Adenocarcinoma
Neoplasms, Ductal, Lobular, and Medullary
Kidney Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Kidney Diseases
Urologic Diseases
Gemcitabine
Bevacizumab
Antineoplastic Agents, Immunological
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents